Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell counts: Correlations with various parameters of disease progression

AIDS Research and Human Retroviruses

Volumn 12, Issue 6, 1996, Pages 497-506

  Dalod, Marc ^a   Fiorentino, Susana ^a   Delamare, Catherine ^b   Rouzioux, Christine ^b   Sicard, Didier ^a   Guillet, Jean Gerard ^a   Gomard, Elisabeth ^a  

^a Hôpital Cochin ^*  (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; CELL COUNT; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; SEROCONVERSION; T LYMPHOCYTE SUBPOPULATION; VIRUS ISOLATION;

ANTIGENS, CD28; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PROVIRUSES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VIREMIA;

EID: 0029983022     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.497     Document Type: Article

References (39)

1. Sheppard HW, William WS, Ascher MS, Vittinghoff E, and Winkelstein W: The characterisation of non-progressors: Long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993;7:1159-1166.
2. Schrager LK, Young JM, Glenn Flower M, Mathieson BJ, and Vermund S: Long-term survivors of HIV-1 infection: Definitions and research challenges. AIDS 1994;8:(Suppl.):S95-S108.
3. Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, Birx D, Farzedagen H, Margolick J, Quinn T, Davis B, Bagsara O, Pomerantz R, and Viscidi R: Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses 1994;10:1703-1711.
4. Huang Y, Zhang L, and Ho DD: Characterisation of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995;69:93-100.
5. Kirchhoff F, Greehough TC, Brettler DB, Sullivan JL, and Desrosiers RC: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. New Engl J Med 1995;332:228-232.
6. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Kieny M-P, Dreyfus F, Saimot A-G, Sereni D, Sicard D, Levy J-P, and Gomard E: Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 1992;6:1249-1258.
7. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Iniotaki-Theodoraki A, and Kosmidis J: Downregulation of CD28 surface antigen on CD4+ and CD8+ lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 1994;7:245-253.
8. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, and Eegeland T: Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: Functional and clinical correlation. J Infect Dis 1994;169:730-738.
9. Landay AL, Mackewicz CE, and Levy JA: An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993;69:106-116.
10. Culmann B, Gomard E, Kiény M-P, Guy B, Dreyfus F, Saimot AG, Sereni D, Sicard D, and Levy J-P: Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol 1991;146:1560-1565.
11. Nunes J, Klasen S, Ragueneau M, Pavon C, Couez D, Mawas C, Bagnasco M, and Olive D: CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: Analysis of early and late activation events. Int Immunol 1993;5:311-315.
12. Rouzioux C, Puel J, Agut H, Brun-Vénizet F, Ferchal F, Tamalet C, Descamps P, and Fleury H: Comparative assessment of quantitative HIV viraemia assays. AIDS 1992;6:373-377.
13. Brinchmann JE, Gaudernack G, Thorsby E, Jonassen TO, and Vartdal F: Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells. J Virol Methods 1989;25:293-300.
14. Rouzioux C: Prevention of maternal HIV transmission. Practical guidelines. Drugs 1995;49 (Suppl. 1):17-24.
15. Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adriaanse H, Malek L, Sooknanan R, and Lens R: NASBA™ isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35:273-286.
16. Sninsky J and Kwok S: The application of quantitative polymerase chain reaction to therapeutic monitoring. AIDS 1993;7 (Suppl. 2):S29-S34.
17. - lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol 1996; in press.
18. Ho DD, Yoshiyama H, Mori H, Daar ES, and Cao Y: Quantitation of HIV-1: Significance in pathogenesis and therapy. In: Viral Quantitation in HIV Infection. (Andrieu J-M, ed.). John Libey Eurotext, Paris/France, 1991, pp. 3-7.
19. Bagnarelli P, Menzo S, Valenza A, Manzin A, Giacca M, Ancarani F, Scalise G, Varaldo PE, and Clementi M: Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992;66:7238-7335.
20. Gupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, and Rinaldo C: Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology 1993;196:586-595.
21. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Ly TD, Goujard C, Guillet J-G, and Gomard E: Different patterns of HIV-1-specific cytotoxic T lymphocyte activity after primary infection. AIDS 1995;9:421-426.
22. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MBA: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
23. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and HO DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
24. Carmichael A, Jin X, Sissons P, and Borysiewicz LK: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
25. Michael NL, Chang G, Ehrenberg PK, Vahey MT, and Redfield RR: HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Defic Syndr 1993;6: 1073-1085.
26. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, and Fauci SF: HIV infection is active and progressive in lymphoid tissue during the clinically latent state of disease. Nature (London) 1993;362:355-358.
27. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, and Haase HT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
28. Gruters RA, Terpstra FG, de Goede REY, Mulder JW, De Wolf F, Schellekens PTA, van Lier RAW, Tersmette M, and Miedema F: Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS 1991;5:837-844.
29. Greenough C, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, and Sullivan JL: Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. Aids Res Hum Retroviruses 1994;4:395-403.
30. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots L, Davey V, Pantaleo G, Deamrest JF, Carter C, Wannebo C, Yannelli JR, Rosenberg SA, and Clifford Lane H: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV-1 variants and subsequent disease progression. Nature Med 1995;1:330-336.
31. Lucas PJ, Negishi I, Nakayama K, Fields LE, and Loh DY: Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol 1995;154:5757-5768.
32. Ho HN, Hultin LE, Mitsuyasu RT, Matud JL, Hausner MA, Bockstoce D, Chou CC, O'Rourke S, Taylor JMG, and Giorgi JV: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993;150:3070-3079.
33. Giorgi JV, Liu Z, Hultin E, Cumberland WG, Hennessey K, and Detels R: Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognosis value of low CD4+ T cell levels: Result of 6 years of follow-up. J Acquir Immune Defic Syndr 1993;6:904-912.
34. Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksenhendler E, Autran B, and Wain-Hobson S: HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994;78:373-387.
35. - T-cells. AIDS 1994;8:431-441.
36. Zinkernagel RM and Hengartner H: T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS. Immunol Today 1994;15:262-268.
37. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
38. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
39. Giorgi JV, Ho HN, Hirji K, Chou CC, Hultin LE, O'Rourke S, Park L, Margolick JB, Ferbas J, Phair JP, and group tMACS: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: Development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994;170:775-781.